IMRT Treatment in Raipur

Intensity-Modulated Radiation Therapy or IMRT delivers precisely shaped doses of radiation to tumours while minimising exposure to surrounding healthy tissue. Each beam is divided into hundreds of small segments, each independently modulated to deliver a different intensity, allowing the dose to conform tightly to the three-dimensional tumour shape.

IMRT sculpts the dose in three dimensions, wrapping around critical structures and accommodating anatomical complexity that conventional techniques cannot safely manage. It is now the standard of care for head and neck cancers, prostate cancer and many other sites where normal tissue protection is critical.

Why Choose Ramkrishna CARE Hospitals for IMRT Treatment in Raipur?

Ramkrishna CARE Hospitals combines advanced radiation technology with expert oncology care to deliver highly precise, personalised IMRT treatment:

• Elekta Versa HD linear accelerator: IMRT is delivered on the Elekta Versa HD. The Agility MLC moves at leaf speeds up to 6.5 cm/s with dynamic jaw tracking enabling up to 6× more modulations per arc than standard systems, for tighter dose conformality and superior normal tissue sparing
• IntelliBeam - 1,024 control points per arc: Far exceeding the 180 control points conventional systems provide, enabling precise dose sculpting around the brainstem, optic chiasm and carotid arteries
• Monaco Monte Carlo dose planning: The gold-standard Monte Carlo algorithm models photon and electron interactions in tissue with greater accuracy than conventional algorithms particularly in lung, bone, and air cavities, ensuring that what is planned is what is delivered
• PET CT target delineation - uMI 550: the uMI 550 Digital PET CT identifies metabolically active tumour volumes that are not visible on CT or MRI alone particularly in head and neck cancer and lymphoma. PET-defined volumes imported into Monaco reflect true biological disease extent rather than anatomical approximation
• Precise positioning: Corrects patient position in all six degrees of freedom to submillimeter accuracy before each fraction. Essential for IMRT where steep dose gradients protecting normal tissue mean small positioning errors can underdose tumour or overdose critical structures
• Automated quality assurance: Standardised automated machine QA before each session, with in-vivo EPID dosimetry comparing delivered dose to the plan-predicted dose in real time - a safety net for every fraction
• Multidisciplinary treatment planning: IMRT target volumes and dose constraints are agreed at multidisciplinary tumour board before planning begins, ensuring that radiation oncologists, surgeons and medical oncologists are aligned on what needs to be treated, what needs to be protected, and how the radiation integrates with surgery or chemotherapy.

Conditions Treated with IMRT

IMRT is the radiation technique of choice when the tumour is geometrically complex, when critical structures are in close proximity to the treatment target or when dose escalation above conventional levels is clinically indicated:

• Head and neck cancers: Oropharynx, nasopharynx, larynx, oral cavity and thyroid cancer, where IMRT allows salivary gland sparing and reduction of xerostomia.
• Prostate cancer: IMRT enables dose escalation to the prostate while limiting rectal and bladder doses, reducing rates of long-term urinary and bowel toxicity.
• Brain tumours: Where proximity of optic structures, brainstem and hippocampi demands the highest dose conformality
• Lung cancer: IMRT and its volumetric variant VMAT are used for locally advanced lung cancer, allowing dose escalation while limiting dose to the contralateral lung, heart, oesophagus and spinal cord
• Breast cancer: Post-mastectomy or breast-conserving radiotherapy, particularly for left-sided tumours where cardiac dose reduction is clinically important
• Rectal and anal cancer: Concurrent chemoradiation with IMRT reduces doses to the small bowel, femoral heads and external genitalia compared with conventional pelvic radiotherapy
• Gynaecological cancers: Cervical and endometrial cancer, where IMRT significantly reduces gastrointestinal toxicity compared to conventional pelvic techniques
• Lymphoma: Involved-field and involved-site radiotherapy with IMRT minimises dose to heart, lungs and remaining uninvolved nodal regions
• Spinal and paraspinal tumours: IMRT allows dose escalation to spinal cord and vertebral column tumours while precisely avoiding the cord tolerance dose
• Paediatric tumours: Reducing normal tissue high-dose volumes limits the growth, neurocognitive and endocrine late effects of childhood cancer treatment.

Symptoms That Indicate IMRT May Be Needed

IMRT is selected based on cancer type, stage and treatment objectives, not symptoms directly. The following presentations commonly lead to IMRT-based treatment:

• Persistent hoarseness, difficulty swallowing or neck mass in head and neck cancer where IMRT allows high dose treatment while preserving parotid function.
• Localised prostate cancer identified on biopsy, particularly when dose escalation is planned to reduce recurrence risk
• Brain tumour confirmed on MRI, particularly when close to the optic apparatus, brainstem or motor cortex
• Locally advanced lung cancer not suitable for surgery where IMRT or VMAT enables definitive chemoradiation
• Pelvic malignancy, including rectal, cervical or endometrial cancer, where radiation is part of the definitive or adjuvant treatment and bowel dose reduction is a priority
• Post-operative radiation after breast surgery, particularly on the left side where cardiac dose is a concern.

Diagnosis and Preparation Before IMRT

Careful evaluation & treatment preparation are essential before IMRT so that radiation is delivered precisely to the tumour while protecting surrounding healthy tissues. Evaluation includes:

• Histological confirmation: Tissue biopsy confirming the cancer diagnosis and subtype, which determines the appropriate radiation dose and fractionation schedule
• Cross-sectional imaging: High-resolution CT and MRI of the treatment site provide anatomical detail for tumour delineation and organ-at-risk contouring. Specific protocols, including MRI for prostate, brain, and rectal cancer; contrast-enhanced CT for lung and head and neck, are selected based on the tumour site
• PET CT - uMI 550: Defines the metabolically active tumour volume for head and neck, lung, and lymphoma cases where nodal involvement may not be apparent on anatomical imaging. PET-defined targets are more accurate than CT-derived volumes alone
• CT simulation: A dedicated planning CT with the patient in their treatment immobilisation device. Custom shells or positioning systems are fabricated and used for every session to ensure consistent position throughout the course.

IMRT Treatment Procedure

Treatment procedure steps are:

• Target delineation: The radiation oncologist contours the gross tumour volume, clinical target volume and planning target volume on the planning CT, integrating MRI and PET CT information
• Dose optimisation: Monaco optimises beam angles, leaf positions and intensities to achieve a prescribed target dose while meeting all organ-at-risk constraints. 
• Daily treatment setup: Cone-beam CT acquired before each session is compared with the planning CT. Small adjustments are made if needed to ensure accurate radiation delivery.
• Treatment delivery: The Versa HD delivers highly targeted radiation from multiple angles using VMAT (Volumetric Modulated Arc Therapy). Each treatment session is painless, with delivery times of two to four minutes per arc.

Risks and Possible Complications of IMRT

IMRT reduces radiation toxicity significantly versus conventional radiotherapy. Some risks are inherent to any radiation treatment:

• Acute skin reactions: Redness, dryness and irritation in the radiation field that are typically resolving within four to six weeks of completing treatment
• Fatigue: Cumulative across the treatment course and usually resolving over weeks to months after completion
• Site-specific acute toxicity: Mucositis, dysphagia and xerostomia in head and neck IMRT; urinary frequency & loose stools in pelvic IMRT; cough or oesophageal irritation in thoracic IMRT
• Late effects: Possible fibrosis, dry mouth and site-specific long-term changes. Late effects are substantially lower with IMRT than conventional radiation due to improved normal tissue sparing
• Secondary malignancy risk: A small, long-term risk from radiation exposure to surrounding tissues, relevant particularly in younger patients treated with curative intent.

Benefits of IMRT

Key advantages are:

• Dose escalation: Higher radiation doses than safe with conventional techniques, improving tumour control without proportionally increasing toxicity
• Superior normal tissue protection: Significantly reduced doses to salivary glands, rectum, bladder, spinal cord and other structures compared with conventional radiotherapy
• Complex tumour geometry: IMRT treats concave or irregularly shaped targets wrapping around critical structures where conventional radiation would cause unacceptable damage.
• Reduced acute and late toxicity: Better quality of life during and after treatment than conventional radiation for the same indication
• Compatible with concurrent systemic therapy: Improved normal tissue protection allows safer concurrent chemotherapy or immunotherapy.
• Outpatient delivery: Each fraction takes 15 to 30 minutes, so patients maintain most normal activities throughout the treatment course.

Side Effects of IMRT

Side effects of IMRT are site specific and generally less severe than with conventional radiation:

• Head and neck IMRT: Mucositis, xerostomia (reduced with parotid-sparing IMRT), dysphagia, neck skin reaction, fatigue and taste changes. Late effects like mild persistent dry mouth, fibrosis and dental complications if oral hygiene and fluoride prophylaxis are not maintained
• Pelvic IMRT: Urinary frequency, loose stools, perineal skin reaction and fatigue. Late effects substantially lower than conventional pelvic radiation, including reduced small bowel obstruction, chronic proctitis and bladder dysfunction
• Thoracic IMRT: Oesophagitis, cough and fatigue. Radiation pneumonitis risk is reduced by IMRT's ability to limit lung volumes receiving high doses
• Brain IMRT: Fatigue, headache and temporary hair loss in the treatment field. Hippocampal-sparing IMRT reduces cognitive impact when clinically appropriate.

Conclusion

IMRT is qualitatively different from conventional radiotherapy; it makes treatments possible that would otherwise cause unacceptable harm to normal tissues. The ability to sculpt dose in three dimensions and escalate tumour dose while protecting adjacent structures has transformed outcomes across multiple cancer sites.

At Ramkrishna CARE Hospitals, Raipur IMRT is delivered on the Elekta Versa HD, planned with Monaco's Monte Carlo algorithm and guided by PET CT target volumes from the uMI 550. For patients across Chhattisgarh who require precision radiotherapy, this level of technology is available here without the need to travel to a metro city.